CFO of Entrada Therapeutics Executes Routine 10b5‑1 Sale Amid Steady Insider Selling Pattern—No Immediate Alarm for Investors
Insight into Entrada Therapeutics’ CFO Kory James Wentworth’s Rule 10b5‑1 insider sales and what they mean for investors and the company’s future.
3 minutes to read